For the fourth year in a row, BIO is working with bloggers and reporters from around the country (and Canada) to provide attendees with an inside look of what’s happening at the 2012 BIO International Convention in Boston.
Be sure to check out their coverage on BIOtechNOW throughout the event and at their blogs:
Biotech Blog: Yali Friedman & Rolf Taylor
Yali Friedman, Ph.D., is founder of thinkBiotech and chief editor of the Journal of Commercial Biotechnology. His book, Building Biotechnology, is used as a course text in dozens of biotechnology programs. His other books include Best Practices in Biotechnology Education and Best Practices in Biotechnology Business Development. He is also a member of the board of directors and steering group of the Center for Policy on Emerging Technologies, serves on the science advisory board of Chakra Biotech, and also serves as a judge for the Biotech Humanitarian Award and the Maryland Incubator Company of the Year Award.
Rolf Taylor is a development consultant at EASE Fundraising System, a development associate at the American Liver Foundation, and a special projects & vlogger at the Journal of Commercial Biotechnology. He plans and executes communications and development programs to support medical products, devices and diagnostics, association and foundation
The Cross-Border Biotech Blog, Christian Hartmann
Christian Hartmann has worked for the past 3.5 years at Deloitte Canada as an Account Manager supporting the National Life Sciences and Mining Practices. He has worked on large pharmaceutical accounts and works to develop relationships with early stage biotechnology companies. He also represents Deloitte at key industry events including BioFinance and BIO. Christian received his diploma in Biotechnology from Seneca College and has worked in industry as part of the team that developed an early detection kit for Myocardial Infarction at Spectral Diagnostics. He has also owned and operated a business in the Health Food industry gaining approvals from Health Canada, FDA, CRA and CITIES to import and distribute a novel plant based supplement product for sale in Canada and the U.S.
Fierce Biotech, John Carroll
John D. Carroll is a biotech analyst with 32 years of prize-winning experience in journalism. Appointed editor of FierceBiotech in 2003, he has covered genomics, biotechnology, healthcare and other business topics for Managed Care, American Banker, Small Times, and Local Business.com, He has also contributed stories from Central America and Ireland to the Dallas Morning News and Time and wrote for the Houston Press and other leading publications. He spent six years as editor and publisher of the Dallas Business Journal, was publisher of Texas Business and early in his career was part of a Pulitzer Prize-winning team of reporters and editors at the Kansas City Star & Times. He enjoys hiking, traveling and spending time with his family. John is based in Vermont and Texas.
Genome Alberta, Mike Spear
Mike Spear is Director of Corporate communications at Genome Alberta. After an extensive career in the media as a Producer, Executive Producer, and Program Manager, Mike moved over to other side of the journalists microphone when he joined the non-profit Alberta Beef Producers as Communications and Marketing Manager. After guiding and developing a new marketing plan to lead them through to 2009, it was time to look for a new challenge and he landed here with Genome Alberta in July of 2007. As Director of Corporate Communications Mike is an important part of Genome Alberta’s goal of “taking the Alberta Advantage to the world of international science”.
Life Science Leader, Rob Wright
As the chief editor of Life Science Leader magazine, Rob develops editorial content in the pharmaceutical and biotechnology industries. The focus of their audience is management level decision makers, such as the c-suite and director level, providing information regarding pre-clinical drug discovery and development up to commercialization. Life Science Leader is a B2B publication having 25,000 subscribers in the U.S. and over 50,000 globally via their digital version. Rob has 17 years of pharmaceutical industry experience in variety of roles, including sales, training, and management with OTC and prescription products, medical device, surgical implants and diagnostic tests. Previous publications primarily focused on the post commercialization aspect of the industry. Additional experience includes serving as a speaker at a variety of international marketing and pharmaceutical conferences.
Lillypad, Yasmein Asi & Robyn Orth
Yasmein Asi is a digital government affairs consultant at Eli Lilly and Company. Before being hired full-time in June 2011, she was a government affairs intern at Eli Lilly. She received her BA in Politic Science and Communication in 2008 before receiving her Masters in International Policy & Development.
Robyn Orth is a consultant covering digital government affairs at Eli Lilly and Company. Before being hired full-time, she was an international affairs intern. She received a BA in Latin American Studies and History at Tulane University before earning an MA in Latin American Studies at Georgetown University. Robyn specializes in Latin American studies, networking, administration and research.
MIT Technology Review, Susan Young
Susan Young is the biomedicine editor for Technology Review and looks for stories where technology stands to improve human health or advance our understanding of the human condition. She joined Technology Review in March 2012 after a brief stint in the Washington, D.C., news bureau of the scientific journal Nature.
Patent Baristas, Stephen Jenei
Editor-in-Chief Barista Stephen Jenei is the founder and owner of Patent Baristas. He is also a patent attorney and Owner of the innovative law firm Jenei LLC. When not serving up patent chat over a cup of java, he’s handling a diverse intellectual property practice in the biotechnology, pharmaceutical and chemical fields for leading universities, research hospitals and research institutes, as well as biotechnology and pharmaceutical companies ranging from start-up to Fortune 500 companies. He works closely with biotechnology and emerging growth companies to brew up successful new business models, execute strategic intellectual property protection and litigation, and structure and negotiate technology transactions.
Patent Docs, Kevin Noonan & Don Zuhn
Kevin Noonan has extensive experience in biotechnology and the chemical arts. Dr. Noonan brings more than 10 years of experience as a molecular biologist working on high-technology problems to his legal work. He has wide experience in all aspects of patent prosecution, interference, litigation, and client counseling on validity, infringement, and patenting strategy matters. He represents pharmaceutical and biotechnology companies both large and small, and he is particularly experienced in representing university clients in both patent prosecution and licensing to outside investors.
Don Zuhn has more than a decade of experience in all aspects of patent prosecution, litigation, counseling, and licensing. He represents a variety of clients, including biotechnology and pharmaceutical companies both large and small, and universities. Don joined MBHB in 1998. He maintained a full-time position as a law clerk while attending law school at night until his graduation in 2002.
Snapshot, Betsy Raymond Stevenson
RaymondStevenson Healthcare Communications’ client roster includes leading pharmaceutical and biotechnology companies. Prior to founding RaymondStevenson in 2007, Betsy worked with Pfizer Inc’s Corporate Communications group, where she developed strategy and directed international and top-tier media relations for the company’s Oncology and Central Nervous System portfolios and served as media counsel for Pfizer’s Chief Medical Officer and Senior Vice President Worldwide Development. Betsy led the team that developed Pfizer’s U.S. Research and Development communications and re-branding strategies for the company’s Warner-Lambert merger and Pharmacia acquisition.
Trade Secrets, Brady Huggett
Brady Huggett is Managing Editor for BioWorld Today, BioWorld Financial Watch, BioWorld Week and BioWorld International, and serves as overseer for the organization’s sourcebooks and BioWorld Phase III Report.
Xconomy, Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. Before joining Xconomy, he was the U.S. biotechnology reporter for Bloomberg News, based in San Francisco. There, he led coverage of major medical meetings and broke news about the industry’s top companies. His stories appeared in The New York Times, Los Angeles Times, Boston Globe, and International Herald Tribune. Before that, his passionate coverage of biotechnology won many awards for The Seattle Times.
While at the Times, Luke was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award, the Sigma Delta Chi prize from the Society of Professional Journalists, the Society of American Business Editors and Writers award, an honorable mention Gerald Loeb Award, and was nominated for the Pulitzer Prize in public service. At Xconomy, he was honored in 2012 as a finalist for the Gerald Loeb Award, and received a SABEW award for biotech columns.
Now, let’s get to down to business.